Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAHANCA 30: Nimorazole in Hypoxia-profile Guided HNSCC
NCT02661152Phase 3Completed
- Sponsor
- Danish Head and Neck Cancer Group
- Start
- Sep 2016
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nimorazole in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Danish Head and Neck Cancer Group. Primary endpoint: Locoregional tumour control at 5 years. Started Sep 2016; status: completed.
02
Drugs
nimorazole
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02661152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661152.